Priothera begins subject enrolment in AML therapy trial

Priothera has enrolled the first participant in the Phase IIb/III MO-TRANS global trial of mocravimod in acute myeloid leukemia (AML) patients undergoing allogeneic haematopoietic cell transplant (HCT).